Four weeks after Hurricane Sandy slammed into the Eastern U.S., the full scope of the superstorm's impact on one of the busiest clinical trials centers in the world remains unknown. The discovery of thousands of drowned lab mice in the bowels of New York University's (NYU) Smilow Research Building following Sandy's storm surge the night of Oct. 29 suggested the region's medical infrastructure would be damaged beyond bricks and mortar. Read More
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16.1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease. Read More
Many of the scientists who are attempting to harness stem cells for tissue repair and regeneration do so via a transplantation approach. That pathway consists of finding a source of stem cells and transplanting them. Read More
Published results from preclinical work with the company's oral Aurora A angiogenic kinase inhibitor boosted shares of EntreMed Inc., leaving the stock (NASDAQ:ENMD) to close Monday at $1.73, up 34 cents, or 24.5 percent, after trading as high as $1.99. Read More
• Erytech Pharma, of Lyon, France, said it entered a definitive agreement granting Orphan Europe, part of the Recordati Group, of Milano, Italy, exclusive rights for the commercialization and distribution of Graspa in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in Europe. Read More
• The Belgian Federal Agency for Medicines and Health Products gave authorization to Cardio3 BioSciences, of Mont-Saint-Guibert, Belgium, to begin a Phase III trial of C3BS-CQR-1, an autologous stem cell therapy, for congestive heart failure. Read More
• Ranbaxy Laboratories Inc., of Gurgaon, India, launched Absorica (isotretinoin) capsules for severe, recalcitrant, nodular acne in patients younger than 12. Read More
• The Journal of the American Academy of Dermatology published results from two pivotal trials by Valeant Pharmaceuticals International Inc., of Montreal, of efinaconazole 10 percent topical solution for onychomycosis, a nail infection caused by fungi. Read More
